Morgan Ebert, Managing Editor

At the 2023 Pediatric Academic Societies Meeting, presenters provided the benefits of breastfeeding, along with some useful tips for lactation and how to best help your breastfeeding patients.

Contemporary Pediatrics® Editorial Advisory Board Member Steven Selbst, MD, gives a glimpse into some research he was involved in regarding physician burnout at the 2023 Pediatric Academic Societies meeting.

Contemporary Pediatrics® Editorial Advisory Board Member Steven Selbst, MD, discusses what sessions he is looking forward to the most from this year's Pediatric Academic Societies conference in Washington, DC.

Roflumilast is a once-daily, topical phosphodiesterase type 4 (PDE4) inhibitor under development for treatment of inflammatory dermatoses, focusing on the hair-bearing areas including the face, scalp, and trunk.

Following voluntary market withdrawal from Covis Pharma, the FDA has decided to withdraw the approval of Makena and its generics for reducing the risk of preterm birth.

Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor indicated for patients as young at 5 years to control high levels of low-density lipoprotein cholesterol (LDL-C) as a result of HoFH.

A New Drug Application has been submitted to the FDA for potential approval of roflumilast foam 0.3% for the treatment of seborrheic dermatitis in adults and adolescents.

Aflibercept is now approved to treat 5 retinal conditions caused by ocular angiogenesis.

If approved, according to AbbVie, linaclotide would be the first prescription therapy for FC in this patient population.

Recently announced data from the INTEGUMENT-1 phase 3 clinical trial demonstrated positive safety and efficacy results for atopic dermatitis patients 6 years and older treated with roflumilast cream (Arcutis Biotherapeutics).

Learn about the most recent news discussed at the 2022 AAP National Conference and Exhibition.

An advisory panel for the US Food and Drug Administration voted 14-1 to withdraw 17α-hydroxyprogesterone caproate (Makena; Covis Pharma) from the market.

Gregg Sylvester, MD, MPH, chief health officer at CSL Seqirus, discusses an FDA-approved cell-based flu vaccine for children as young as 6 months, trends in childhood vaccination rates, and how to prepare for the upcoming flu season.

Olipudase alfa-rpcp (Xenpozyme; Sanofi) is the first disease-specific, and now, only approved therapy for the treatment of acid sphingomyelinase deficiencies in pediatric and adult patients.

Marina Sirota, PhD, associate professor of pediatrics at the University of California, San Francisco, spoke about the new March of Dimes Prematurity Research Center at UCSF and the impact they hope their research will have on the future of preterm birth.

Craig Shapiro, MD, pediatric infectious disease specialist at Nemours Children's Hospital, sits down to discuss the recent uptick in pediatric monkeypox cases and explains what to do if you suspect your patient to have monkeypox.

Novavax joins the growing list of COVID-19 vaccines including vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen

The FDA has granted Emergency Use Authorization (EUA) of the JYNNEOS vaccine for pediatric patients <18 years who are at high risk of monkeypox infection.

If approved, ibrexafungerp would be the first and only approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the prevention of recurrent vulvovaginal candidiasis (RVVC).

This decision by the US Food and Drug Administration marks the first approved treatment for pediatric lupus nephritis.

VIVUS LLC announced the US Food and Drug Administration's approval of QSYMIA (phentermine and topiramate extended-release capsules) for the treatment of obesity in adolescents ages 12 to 17 years.

If approved, trofinetide has the potential to be a new treatment for Rett syndrome in pediatric and adult patients 2 years and older.

Perrigo’s HRA Pharma has submitted an application to the US Food and Drug Administration (FDA) for possible future approval of the first-ever OTC birth control pill.

US President Joe Biden signed an executive order Friday protecting nationwide access to abortion and contraception.

Currently approved for the treatment of vulvovaginal candidiasis, and if the sNDA is approved, ibrexafungerp would be the first and only oral non-azole medication for the prevention of recurrent VVC.

A presentation at the 2022 American College of Obstetricians and Gynecologists’ Annual Clinical & Scientific Meeting discussed the recent updates in contraceptives including new nonhormonal intrauterine devices.

An interview with Adelaide Hebert, MD, how environmental factors may play a role in flare ups.

The US Food and Drug Administration has approved halobetasol propionate foam, 0.05%, a potent topical corticosteroid, for the treatment of plaque psoriasis in adolescent patients.